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Abstract
Background: Activation of the epidermal growth factor receptor (EGFR) triggers downstream signaling
pathways that regulate many cellular processes involved in tumour survival and growth. Gefitinib ('Iressa') is an
orally active tyrosine kinase inhibitor (TKI) targeted to the ATP-binding domain of EGFR (HER1; erbB1).
Methods: In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to
measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine,
oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and
ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer
(NSCLC) and sarcoma. The IC50 and IC90 were calculated for each single agent or combination. To allow
comparison between samples the IndexSUM was calculated based on the percentage tumour growth inhibition
(TGI) at each test drug concentration (TDC). Gefitinib was tested at concentrations ranging from 0.0625–2
microM (TDC = 0.446 microg/ml). This study represents the first use of a TKI in the assay.
Results: There was heterogeneity in the degree of TGI observed when tumours were tested against single agent
gefitinib. 7% (6/86) of tumours exhibited considerable inhibition, but most showed a more modest response
resulting in a low TGI. The median IC50 value for single agent gefitinib in all tumours tested was 3.98 microM.
Interestingly, gefitinib had both positive and negative effects when used in combination with different cytotoxics.
In 59% (45/76) of tumours tested, the addition of gefitinib appeared to potentiate the effect of the cytotoxic agent
or combination (of these, 11% (5/45) had a >50% decrease in their IndexSUM). In 38% of tumours (29/76), the TGI
was decreased when the combination of gefitinib + cytotoxic was used in comparison to the cytotoxic alone. In
the remaining 3% (2/76) there was no change observed.
Conclusion: The in vitro model suggests that gefitinib may have differential effects in response to concomitant
cytotoxic chemotherapy with the agents tested during this study. The mechanism involved may relate to the effect
of TKIs on growth rate versus their effect on the ability of the cell to survive the stimulus to apoptosis produced
by chemotherapy.
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The epidermal growth factor receptor (EGFR) is involved
in many cellular processes including cell proliferation,
motility, adhesion and angiogenesis via the activation of
three pathways: phosphatidylinositol-3 kinase (PI3)/Akt
pathway, the Jak/STAT pathway and the ras/raf pathway.
EGFR is expressed or highly expressed in a variety of
human tumours including non-small-cell lung cancer
(NSCLC), breast, bladder, ovarian and head and neck [1]
and is therefore a promising target for cancer therapy.
Gefitinib ('Iressa') is an EGFR-tyrosine kinase inhibitor
(EGFR-TKI) that competitively inhibits binding of ATP at
the ATP site on EGFR. It also displays remarkable selectiv-
ity for EGFR (IC50 = 0.033 microM) compared with other
receptor tyrosine kinases (RTKs) that share sequence
homology in the ATP binding domain [2]. In pre-clinical
studies, gefitinib has demonstrated in vitro growth inhibi-
tion against a variety of human cell lines including
NSCLC, ovarian, breast, colon and head and neck and is
active in a range of xenograft models, including breast,
colon and prostate [3]. Phase II trials with gefitinib mon-
otherapy have produced encouraging results with clini-
cally significant benefits observed, such as disease control
rates at 250 mg/day gefitinib of 54% and 42% in IDEAL 1
and IDEAL 2, respectively [4,5]. Results from Phase III tri-
als investigating gefitinib in combination with cisplatin
and gemcitabine (INTACT 1) [6] and gefitinib in combi-
nation with paclitaxel and carboplatin (INTACT 2) [7] in
NSCLC concluded there was no added benefit in patients
receiving chemotherapy plus gefitinib; however the toler-
ability of gefitinib was confirmed.
At present, there is conflicting evidence relating the activ-
ity of gefitinib directly to the levels of EGFR expression.
One group found that the concentration of gefitinib
required to inhibit ligand-independent growth by 50%
(IC50) in four bladder cancer cell lines ranged from 1.8–
9.7 microM and correlated with EGFR protein and tran-
script level [8]. However, another study using human
tumour xenografts found that gefitinib caused growth
inhibition of tumours and enhancement of the activity of
a number of cytotoxic drugs, but neither was dependent
on high levels of EGFR expression [9]. Moreover, no con-
sistent association was demonstrated between EGFR
expression and clinical outcome in IDEAL 1 and 2 [10].
Alternative explanations for the activity of gefitinib in sys-
tems where EGFR is not over expressed include inhibition
of EGFR pathway activation mediated by increased levels
of receptor ligands e.g. epidermal growth factor (EGF) and
transforming growth factor-alpha (TGF-alpha); het-
erodimerization with HER2 and cross talk with heterolo-
gous receptors; and EGFR mutations yielding a
constitutively active receptor that is not down-regulated
by endocytosis [11]. There is evidence that the ras/raf
pathway mediates proliferation [12], whereas the PI3/Akt
pathway is essential for cell survival and may be constitu-
tively activated in many tumours by loss of PTEN [13].
We have previously shown that the ATP-based tumour
chemosensitivity assay (ATP-TCA) can be used to measure
the effects of cytotoxic agents and antibodies against
human tumour-derived cells, and that this matches clini-
cal outcome in a number of tumour types [14,15]. Use of
the assay to direct choice of chemotherapy has been
shown to improve response rate and progression-free sur-
vival in ovarian cancer [16,17] and a fully randomized
trial of assay-directed versus physician's choice of chemo-
therapy for platinum-resistant ovarian cancer is in
progress [18]. The assay system has been used to assist the
development of a number of new agents and combina-
tions [19,20], but this represents the first use of a TKI in
the assay.
EGF and TGF-alpha, ligands of EGFR, act as survival fac-
tors for many cells as well as growth factors. As many cyto-
toxic agents induce apoptosis, gefitinib may be able to
potentiate their effects by reducing survival stimuli. The
current pilot study was undertaken to assess the effect of
gefitinib in combination with existing chemotherapeutic
agents (cisplatin, gemcitabine, oxaliplatin, treosulfan)
against a wide range of tumour types.
Methods
Tumours
A total of 86 tumours (57 females:29 males) were tested
in this study, with a median age of 59 years (range 21–90).
The samples tested consisted of the following tumour
types; breast adenocarcinoma (n = 8), colorectal carci-
noma (n = 18), cutaneous melanoma (n = 7), NSCLC (n
= 1), oesophageal adenocarcinoma (n = 4), ovarian carci-
noma (n = 26), sarcoma (n = 2), squamous cell carcinoma
(n = 2), sweat gland carcinoma (n = 1), uveal melanoma
(n = 12) and carcinoma of unknown primary site (n = 5).
The 26 ovarian carcinomas were all recurrent stage 3/4
cancers and 25/26 were pre-treated (11 with carboplatin
and 14 with carboplatin + paclitaxel). Of the remaining
samples, 10/86 had been treated with a variety of chemo-
therapy regimens and some patients had more than one
treatment; epirubicin + cisplatin + 5-Fluorouracil (5-FU)
(n = 3), epirubicin + cyclophosphamide (4-HC) (n = 1),
4-HC+methotrexate+5-FU (CMF) (n = 2), cisplatin +
vinorelbine (n = 1), mitomycin C + 5-FU (n = 1), mitox-
antrone + paclitaxel (n = 1), chlorambucil (n = 1), 4-HC
(n = 1) and irinotecan (n = 1). The remaining 51 patients
had no previous treatment. In each case only tumour
material not required for diagnosis was sent for ATP-TCA,
and in all cases consent had been obtained and permis-
sion had been granted by the local ethics committee.Page 2 of 8
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The ATP-TCA was performed as previously published
[14,21]. Solid tumour or ascites samples were transported
to the laboratory in transport medium, consisting of Dul-
becco's Eagles Media (DMEM) (Sigma, UK; D6171). Solid
samples were dissected under sterile conditions in a BioQ
Microfuge Class II Hood and placed into a 0.75 mg/ml
collagenase solution (Sigma, UK; C8051) for enzymatic
dissociation overnight. Following dissociation, the single
celled suspension or ascites sample was washed using
DMEM supplemented with 1 M HEPES, (Sigma, UK;
H0887), 100 IU/mL penicillin, 10 mg/mL streptomycin
(Sigma, UK; P0781) and 10 mg/mL gentamicin (Sigma,
UK; G1272). The final cell suspension was then plated in
96-well polypropylene plates (Corning Life Sciences,
High Wycombe, UK) at 20,000 (solid sample) or 10,000
(ascites sample) cells/well in a serum-free complete assay
medium (CAM, DCS Innovative Diagnostik Systeme,
Hamburg, Germany). Drugs were added to triplicate wells
at serial dilutions corresponding to 200–6.25% of a test
drug concentration (TDC) estimated from pharmacoki-
netic data, which included the degree of protein binding.
Two controls were included in each plate: one with no
drug and consisting of media only (MO), and a maximum
inhibitor (MI) control which killed all cells present. The
plates were incubated for 6 days at 37°C with 5% CO2. At
the end of the incubation period, remaining cells were
lysed by addition of an ATP extraction reagent (DCS Inno-
vative Diagnostik Systeme). An aliquot of the lysate from
each well was added to the corresponding wells of a white
96 well microplate (Thermo Life Sciences, Basingstoke,
UK), followed by addition of luciferin-luciferase reagent.
The light output corresponding to the level of ATP present
was measured in a luminometer (MPLX, Berthold Diag-
nostic Systems, Hamburg, Germany). These data were
transferred automatically to an Excel spreadsheet where
the % inhibition achieved at each concentration tested
was calculated using the equation; 1-(test-MI)/(MO-MI) ×
100. Several parameters of efficacy can be calculated e.g.
IC50 and IC90, however previous ATP-TCA studies have
found that a natural logarithmic sum index (IndexSUM)
calculated by direct addition of the percentage survival at
each concentration tested (Index = 600-
Σb3;%Inhibition6.25...200) provides a better indication
of sensitivity or resistance to different drugs in different
tumour types [22]. The total inhibition of growth resulted
in an index of 0, and no inhibition of growth at any con-
centrations produces an index of 600 [23]. Area under the
concentration-inhibition curve (IndexAUC) was calculated
from the data using the trapezoidal rule.
Data Analysis
The results were entered into an Access 2000 database for
further analysis. Statistical tests were performed using
non-parametric methods.
Drugs
The cytotoxic drugs used in the assay were obtained as
vials for injection and made up according to manufactur-
ers' instructions. Gemcitabine, oxaliplatin and treosulfan
were stored in aliquots at -20°C, while cisplatin was
stored at room temperature. Table 1 shows the 100% TDC
for each of the drugs used. Drug combinations were tested
by combining single agents. The EGFR-TKI, gefitinib
(kindly provided by AstraZeneca) was tested at concentra-
tions ranging from 0.06–2 microM (100% TDC = 0.99
microM).
Immunohistochemistry
Tissue was available for EGFR immunohistochemical
staining in 31/86 (36%) cases comprising of 4 breast car-
cinomas, 12 colon carcinomas, 2 oesophageal carcino-
mas, 2 ovarian carcinomas, 1 sarcoma, 4 skin melanomas,
5 uveal melanomas and 1 carcinoma of unknown primary
site. Paraffin embedded sections of 4 µm thick were
dewaxed and rehydrated in preparation for immunohisto-
chemical staining. Endogenous peroxidase was blocked
using 3% hydrogen peroxide in methanol. The sections
were pretreated with 0.1% Trypsin (CaCl2/Tris buffer
pH8.0) for 10 minutes at 37°C for antigen retrieval.
Immunohistochemical studies were performed according
to manufacturer's instructions of the Vectastain Universal
ABC-AP kit (Vector Laboratories, Burlingame, California,
U.S.A), which uses an avidin-biotin complex method and
Vector red as the chromogen. Monoclonal antibody for
EGFR, Clone E30 (Dakocytomation, Cambridgeshire,
U.K) was used at a dilution of 1:20 and incubated with
sections for 18 hours at 4°C. Positive (squamous cell car-
cinoma tissue) and negative controls were included in
each staining procedure. Samples were assessed by a
pathologist using the H-score. Intensity was graded on a
scale ranging between 0, 1+, 2+ or 3+, (where 1+ equals
weak staining, 2+ equals moderate and 3+ equals intense)
and the proportion of cells stained at the highest intensity.
The two values were then multiplied together to give the
final value.
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able for pAkt staining. Paraffin embedded sections of 4
µm thick were dewaxed and rehydrated in preparation for
immunohistochemical staining. Endogenous peroxidase
was blocked using 3% hydrogen peroxide in methanol.
The sections were pretreated with 0.1 M citrate buffer in a
pressure cooker for 2.5 minutes for antigen retrieval.
Immunohistochemical studies were performed according
to manufacturer's instructions of the Vectastain Universal
ABC-AP kit (Vector Laboratories, Burlingame, California,
U.S.A), which uses an avidin-biotin complex method and
Fuchsin as the chromogen. Phospho-Akt, Ser473 (#9277
L, Cell Signalling, MA. USA) was used at a dilution of 1:50
and incubated with sections for 18 hours at 4°C. Positive
(prostate cancer tissue) and negative controls were
included in each staining procedure. Samples were
assessed as described previously.
Results
Gefitinib showed low inhibition (IndexSUM >300) across
the range of concentrations tested in the ATP-TCA, with
little evidence of increasing inhibition with increasing
drug concentration. 7% (6/86) of tumours exhibited con-
siderable inhibition (>50% inhibition at 100% TDC), but
most showed a more modest response resulting in a low
maximum percentage inhibition (Figure 1). The esti-
mated median IC50 and IC90 value for single agent gefit-
inib in all tumours tested was 3.98 microM (<0.1–69.9
microM) and 6.45 microM (2.4–125.9 microM) respec-
tively. The median IC50 for individual tumour types
tested is shown in Table 2.
There was heterogeneity in the degree of inhibition
observed when tumours were tested against single agent
gefitinib (Figure 2). To compare between tumours, an
IndexSUM of <300 corresponding to 50% inhibition across
the range of concentrations tested was used to compare
results. On this basis, single agent gefitinib was effective
against 5% (4/86) of samples, comprising 1 colorectal
tumour, 1 ovarian tumour, 1 uveal melanoma and 1
unknown primary carcinoma. In 88% (76/86) of samples
there was sufficient material to test gefitinib in combina-
tion with different cytotoxics.
Table 3 shows the median results for single-agent cytotox-
ics tested compared to results when tested in combination
with gefitinib. In samples tested with gefitinib in combi-
nation with cisplatin (n = 6) only 33% (2/6) showed
increased sensitivity (i.e. a decrease in their IndexSUM),
compared to when cisplatin was used alone. The remain-
ing 67% (4/6) showed increased resistance (i.e. an
increase in their IndexSUM). This compares with gefitinib
in combination with oxaliplatin (n = 10) where 90% (9/
10) of samples showed an increase in sensitivity with the
combination, with 1 sample showing a >50% decrease in
the IndexSUM. When gefitinib was combined with gemcit-
abine (n = 2), both samples showed an increase in their
sensitivity.
Of the tumours tested with treosulfan + gefitinib, 38%
(13/34) were of ovarian origin. Of these, 62% (8/13)
showed potentiation, with 1 sample showing a >50%
decrease in IndexSUM. 31% (4/13) showed increased
resistance with the combination in comparison with treo-
sulfan alone and 1 sample showed no change (Figure 3).
Of the remaining samples tested with gefitinib +
Median effect of gefitinib on tumour-derived cells compared with  s nsitive and non-sensitive colorectal tumourFigure 1
Median effect of gefitinib on tumour-derived cells compared 
with a sensitive and non-sensitive colorectal tumour. Error 
bars show 25th and 75th inter-quartile range.
Frequency histogram showing heterogeneity of the IndexSUM for gefitinib alone in all tumours t sted (n = 86)igur  2
Frequency histogram showing heterogeneity of the IndexSUM 
for gefitinib alone in all tumours tested (n = 86).Page 4 of 8
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38% (8/21) showed an increase in their resistance and
one sample showed no change. Figures 4a and 4b show
differential effects of gefitinib in combination with treo-
sulfan in cells derived from a skin melanoma sample (Fig-
ure 4a) and an ovarian carcinoma sample (Figure 4b).
When gefitinib was tested in combination with treosulfan
+ gemcitabine (n = 24), 54% (13/24) showed an increase
in sensitivity, with 3 samples showing a >50% decrease in
their IndexSUM and 46% (11/24) showed an increase in
resistance.
In summary, the addition of gefitinib appeared to poten-
tiate the effect of the cytotoxic agent or combination in
59% (45/76) of tumours tested; of these 11% (5/45) had
a >50% decrease in their IndexSUM. In 38% of tumours
(29/76), the combination of gefitinib + cytotoxic caused
the IndexSUM to increase thereby increasing resistance. In
the remaining 3% (2/76) there was no change observed.
Immunostaining for EGFR was positive in 32% (10/31) of
samples comprising of 1 breast carcinomas, 5 colon carci-
nomas, 1 ovarian carcinoma, 1 sarcoma, 1 skin
Table 2: Median IC50 (microM) and IndexSUM values for single-agent gefitinib for all tumours tested.
Tumour N IC50 (microM) IndexSUM
Breast adenocarcinoma 8 7.27 (6.2–16.9) 607 (500–785)
Colorectal adenocarcinoma 18 3.19 (0.1–52.6) 568 (239–818)
Melanoma – cutaneous (CMEL) 7 2.81 (1.9–29.4) 514 (471–587)
Melanoma – uveal (UMEL) 12 17.10 (0.04–69.9) 595 (187–746)
NSCLC 1 - 396
Squamous cell carcinoma 2 2.83 (2.3–3.4) 462 (454–469)
Oesophageal adenocarcinoma 4 3.58 (2.8–4.4) 602 (456–788)
Ovarian carcinoma 26 3.09 (0.2–23.1) 534 (269–777)
Carcinoma of unknown primary 
site (UPS)
5 4.76 (0.05–14.3) 612 (258–648)
Sarcoma 2 9.8 609 (588–630)
Sweat gland carcinoma 1 24.67 651
(Negative values of IC50 have been excluded as meaningless. Negative values usually resulted from flat concentration – activity curve).
Table 3: Median results for single-agent cytotoxics tested compared with results when tested in combination with gefitinib.





Gefitinib 86 3943 (40–13212) 646 (243–12614) 399 (4–7008) 570 (187–818) -
Cisplatin 6 7937 (4244–9804) 294 (208–557) 132 (84–309) 434 (382–497) -
Cisplatin + gefitinib 6 9006 (1731–
12057)
225 (159–585) 107 (58–325) 486 (351–588) 33% (2/6)
Gemcitabine 2 7127 (498–13756) 764 (206–1321) 382 (30–734) 452 (288–616) -
Gemcitabine + gefitinib 2 12605 (9835–
15374)
211 (201–220) 52 (17–86) 315 (207–422) 100% (2/2)
Oxaliplatin 10 3488 (874–8884) 833 (317–2267) 463 (129–1259) 559 (379–681) -
Oxaliplatin + gefitinib 10 5602 (547–12140) 390 (194–775) 217 (60–431) 447 (310–605) 90% (9/10)
Treosulfan 34 13764 (4351–
18390)
146 (35–616) 53 (4–342) 353 (65–726) -
Treosulfan + gefitinib 34 13656 (4251–
18658)
153 (31–19892) 60 (4–11051) 338 (58–897) 56% (19/34)
Treosulfan + gemcitabine 24 17576 (8107–
19164)
57 (6–200) 13 (3–110) 155 (21–456) -
Treosulfan + gemcitabine+ gefitinib 24 17281 (11402–
19119)
48 (9–206) 9 (4–70) 146 (25–572) 54% (13/24)Page 5 of 8
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Immunostaining for pAkt was positive in 81% (25/31) of
samples comprising of 3 breast carcinomas, 10 colon car-
cinomas, 2 oesophageal carcinomas, 2 ovarian carcino-
mas, 4 skin melanomas, 3 uveal melanomas and 1
carcinoma of unknown primary site. Of the positive sam-
ples, 8 were positive for both antibodies (comprising 1
breast carcinoma, 4 colon carcinomas, 1 ovarian carci-
noma, 1 skin melanoma and 1 carcinoma of unknown
primary site). In 74% (23/31) of samples that were
stained for EGFR and pAkt, there was an IC50, IC90 and
IndexSUM value available for comparison. In all cases
tested there was no relationship with gefitinib activity and
EGFR or pAkt staining.
Discussion
This is the first study in which a TKI has been successfully
tested in the ATP-TCA. ATP-TCA has potential to assist
drug development for TKIs and possibly to direct therapy
for individual patients. It represents one possible answer
to the need for predictive oncology testing of these agents,
and could be performed alongside clinical trials to obtain
correlation data with outcome in patients treated with
gefitinib. However, it is difficult to ascertain whether these
were specific or non-specific effects of gefitinib and
whether similar outcomes would be seen in the clinical
setting. This would need to be determined before using
this test for routine screening. Gefitinib showed activity in
the assay and even though cytotoxic effects were not
expected, in some cases the diminution in ATP levels sug-
gests that these may occur. In general, flat concentration –
activity curves were observed which are consistent with a
cytostatic rather than a cytotoxic effect. Gefitinib alone
showed activity in lung, ovarian and colon carcinomas.
These results were consistent with previous findings in cell
lines [24].
When gefitinib was tested in combination with a limited
number of cytotoxic drugs, increases and decreases in the
activity of the cytotoxic agent were observed. For example,
gefitinib in combination with cisplatin caused 67% of
samples to have a decrease in the activity of the cytotoxic.
This compares with gefitinib in combination with a sec-
ond platinum-containing agent, oxaliplatin, where 91%
of samples showed an increase in the activity of the cyto-
The effect of gefitinib on tumour-derived cells from recur-rent ovarian cancer (n = 13)Figure 3
The effect of gefitinib on tumour-derived cells from recur-
rent ovarian cancer (n = 13). Legend Some tumours show 
increased sensitivity (lower IndexSUM), while others show 
enhanced resistance (higher IndexSUM)
Tumour growth inhibition by gefitinib vs. treosulfan + gefit-inib in 2 different tumour typesFigure 4
Tumour growth inhibition by gefitinib vs. treosulfan + gefit-
inib in 2 different tumour types. Legend Figure 4a shows the 
positive effect of combining treosulfan plus gefitinib in cells 
derived from a skin melanoma compared with figure 4b in 
which the combination of treosulfan plus gefitinib has a nega-
tive effect in cells derived from an ovarian tumour.Page 6 of 8
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virtually ineffective against the cells tested and this is
therefore likely to reflect the effect of the gefitinib alone
(Figure 5). Decreased activity of cytotoxic agents when
these were combined with gefitinib was seen in 4 samples
with cisplatin, 13 with treosulfan, 1 with oxaliplatin and
11 with treosulfan + gemcitabine. This could be detrimen-
tal to patients. It is similar to the effect of tamoxifen treat-
ment on the success of breast cancer chemotherapy [25].
Although there was heterogeneity in the response of
tumours to single agent gefitinib, there was no relation-
ship between immunostaining for EGFR and gefitinib
activity, consistent with other published studies [26].
Sirotnak et al. [9] showed that gefitinib caused growth
inhibition in human tumour xenografts that was not
dependent on high levels of EGFR expression. However,
EGFR activation leads to activation of at least three sepa-
rate second messenger cascades. While the ras/raf pathway
may mediate the proliferative effects, survival signals are
thought be mediated by the PI3/Akt pathway. As cells
have to die in the ATP-TCA to register increased inhibi-
tion, sensitivity might be related to the degree of activa-
tion of the Akt pathway by other mechanisms. Sensitivity
to gefitinib and other non-TKI EGFR inhibitors might
therefore be related to pathway activation assessed by
detection of pAkt, rather than the levels of EGFR expres-
sion. However, this study has not found any such relation-
ship and, when EGFR staining was compared to pAkt
staining there was no correlation between EGFR levels to
pAkt activity. A similar observation was made by Cam-
piglio et al., [27] whose data suggested that neither MAPK
nor pAkt were reliable markers of gefitinib activity. It
should be noted that many receptors lead to Akt
activation and that constitutive activation of the PI3/Akt
pathway may be the result of PTEN inactivation.
Of the 4 samples that had an IndexSUM of <300 and the 6
samples that demonstrated >50% inhibition at 100%
TDC when tested with single agent gefitinib, 2 samples (a
uveal melanoma and an unknown primary) had material
available for immunohistochemical staining with EGFR
and pAkt. The uveal melanoma was negative for EGFR and
positive for pAkt compared to the unknown primary,
which was positive for both EGFR and pAkt. However,
there were samples with similar IHC results that did not
show sensitivity to gefitinib. As the EGFR (HER1) dimer-
izes with the other HER molecules and mediates greater
activity as a heterodimer, it is likely that the expression of
these molecules is also important to the activity of gefit-
inib [12]. Sensitivity to gefitinib is therefore likely to be
the end result of a complex series of interactions within
the cell.
Conclusion
In this study we have found that gefitinib in combination
with different cytotoxic agents (cisplatin; gemcitabine;
oxaliplatin; treosulfan and treosulfan + gemcitabine) is a
double-edged sword: their effect on growth rate may make
some tumours more resistant to concomitant cytotoxic
chemotherapy, while their effect on cytokine-mediated
cell survival (anti-apoptotic) mechanisms may potentiate
sensitivity to the same drugs in tumours from other
individuals.
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